Literature DB >> 23142699

Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors.

Marjo Malinen1, Tiina Jääskeläinen, Mikko Pelkonen, Sami Heikkinen, Sami Väisänen, Veli-Matti Kosma, Kaisa Nieminen, Arto Mannermaa, Jorma J Palvimo.   

Abstract

We searched ERα cistromes of MCF-7 breast cancer cells for previously unrecognized ERα targets and identified proto-oncogene PIM-1 as a novel potential target gene. We show that the expression of PIM-1 is induced in response to estradiol in MCF-7 cells and that the induction is mediated by ERα-regulated enhancers located distally upstream from the gene. In keeping with the growth-promoting role of the PIM-1, depletion of the PIM-1 attenuated the proliferation of the MCF-7 cells, which was paralleled with up-regulation of cyclin-dependent protein kinase inhibitor CDKN1A and CDKN2B expression. Analysis of PIM-1 expression between invasive breast tumors and benign breast tissue samples showed that elevated PIM-1 expression is associated with malignancy and a higher tumor grade. In sum, identification of PIM-1 as an ERα target gene adds a novel potential mechanism by which estrogens can contribute to breast cancer cell proliferation and carcinogenesis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142699     DOI: 10.1016/j.mce.2012.10.028

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  23 in total

1.  Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.

Authors:  Xiuning Le; Rajee Antony; Pedram Razavi; Daniel J Treacy; Flora Luo; Mahmoud Ghandi; Pau Castel; Maurizio Scaltriti; Jose Baselga; Levi A Garraway
Journal:  Cancer Discov       Date:  2016-09-07       Impact factor: 39.397

2.  PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

Authors:  Dai Horiuchi; Roman Camarda; Alicia Y Zhou; Christina Yau; Olga Momcilovic; Sanjeev Balakrishnan; Alexandra N Corella; Henok Eyob; Kai Kessenbrock; Devon A Lawson; Lindsey A Marsh; Brittany N Anderton; Julia Rohrberg; Ratika Kunder; Alexey V Bazarov; Paul Yaswen; Michael T McManus; Hope S Rugo; Zena Werb; Andrei Goga
Journal:  Nat Med       Date:  2016-10-24       Impact factor: 53.440

Review 3.  PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.

Authors:  Sutapa Mahata; Pranab K Sahoo; Ranita Pal; Sinjini Sarkar; Tanuma Mistry; Sushmita Ghosh; Vilas D Nasare
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

Review 4.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

5.  Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis.

Authors:  Xin Zhu; Yunfang Yu; Xiuxiu Hou; Jiajie Xu; Zhuo Tan; Xilin Nie; Zhiqiang Ling; Minghua Ge
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

6.  Expression of androgen receptor and its phosphorylated forms in breast cancer progression.

Authors:  Qinghu Ren; Liying Zhang; Rachel Ruoff; Susan Ha; Jinhua Wang; Shilpa Jain; Victor Reuter; William Gerald; Dilip D Giri; Jonathan Melamed; Michael J Garabedian; Peng Lee; Susan K Logan
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

7.  PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Authors:  Fara Brasó-Maristany; Simone Filosto; Steven Catchpole; Rebecca Marlow; Jelmar Quist; Erika Francesch-Domenech; Darren A Plumb; Leila Zakka; Patrycja Gazinska; Gianmaria Liccardi; Pascal Meier; Albert Gris-Oliver; Maggie Chon U Cheang; Anna Perdrix-Rosell; Manar Shafat; Elodie Noël; Nirmesh Patel; Kristen McEachern; Maurizio Scaltriti; Pau Castel; Farzana Noor; Richard Buus; Sumi Mathew; Johnathan Watkins; Violeta Serra; Pierfrancesco Marra; Anita Grigoriadis; Andrew N Tutt
Journal:  Nat Med       Date:  2016-10-24       Impact factor: 53.440

8.  Nuclear Receptor Signaling Atlas: Opening Access to the Biology of Nuclear Receptor Signaling Pathways.

Authors:  Lauren B Becnel; Yolanda F Darlington; Scott A Ochsner; Jeremy R Easton-Marks; Christopher M Watkins; Apollo McOwiti; Wasula H Kankanamge; Michael W Wise; Michael DeHart; Ronald N Margolis; Neil J McKenna
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

9.  Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.

Authors:  S Kreuz; K B Holmes; R M Tooze; P F Lefevre
Journal:  Mol Cancer       Date:  2015-12-08       Impact factor: 27.401

10.  Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma.

Authors:  Xin Zhu; Jia-jie Xu; Si-si Hu; Jian-guo Feng; Lie-hao Jiang; Xiu-xiu Hou; Jun Cao; Jing Han; Zhi-qiang Ling; Ming-hua Ge
Journal:  J Exp Clin Cancer Res       Date:  2014-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.